Quantum Genomics Société Anonyme
Quantum Genomics Société Anonyme, a healthtech company, develops of drugs to treat cardiovascular diseases. Quantum Genomics Société Anonyme was incorporated in 2005 and is headquartered in Paris, France.
Quantum Genomics Société Anonyme (QNNTF) - Total Liabilities
Latest total liabilities as of December 2024: $2.81 Million USD
Based on the latest financial reports, Quantum Genomics Société Anonyme (QNNTF) has total liabilities worth $2.81 Million USD as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Quantum Genomics Société Anonyme - Total Liabilities Trend (2012–2024)
This chart illustrates how Quantum Genomics Société Anonyme's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Quantum Genomics Société Anonyme Competitors by Total Liabilities
The table below lists competitors of Quantum Genomics Société Anonyme ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grand Green Energy Co., LTD.
TWO:6639
|
Taiwan | NT$211.55 Million |
|
Futura Medical plc
PINK:FAMDF
|
USA | $2.44 Million |
|
STAK Inc. Ordinary Shares
NASDAQ:STAK
|
USA | $13.85 Million |
|
Myseum, Inc.
NASDAQ:MYSE
|
USA | $1.07 Million |
|
Asia Orient Holdings Limited
F:ASD1
|
Germany | €16.25 Billion |
|
Clean Vision Corp
OTCQB:CLNV
|
USA | $36.60 Million |
|
Atlantaa Limited
NSE:ATLANTAA
|
India | ₹3.37 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Quantum Genomics Société Anonyme's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 7.92 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Quantum Genomics Société Anonyme's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Quantum Genomics Société Anonyme (2012–2024)
The table below shows the annual total liabilities of Quantum Genomics Société Anonyme from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.81 Million | -15.09% |
| 2023-12-31 | $3.31 Million | -83.49% |
| 2022-12-31 | $20.05 Million | +73.22% |
| 2021-12-31 | $11.57 Million | +42.06% |
| 2020-12-31 | $8.15 Million | +51.65% |
| 2019-12-31 | $5.37 Million | -18.75% |
| 2018-12-31 | $6.61 Million | +31.06% |
| 2017-12-31 | $5.05 Million | +85.70% |
| 2016-12-31 | $2.72 Million | +7.89% |
| 2015-12-31 | $2.52 Million | -48.42% |
| 2014-12-31 | $4.88 Million | +47.01% |
| 2013-12-31 | $3.32 Million | +68.19% |
| 2012-12-31 | $1.97 Million | -- |